 |
 |
Supporting Business Development for a Unique Protein Drug Optimization Technology
Ambrx made a fundamental advance in protein biosynthesis that enabled scientists to modify existing protein drugs. Now the company needed to optimize its messaging and complement its reach through PR initiatives targeting prospective investors and partners.
READ MORE.
|
|
|
|
 |
|
Enabling New Genome Sequencing Technology to Stand Out in a Crowd
When 454 Life Sciences began developing a next-generation genome sequencer, it was one of several firms working on technology that would reduce the time and cost of sequencing. The company wanted to stand out in a crowded field.
READ MORE.
|
|
|
|
 |
|
Bringing a Biopharmaceutical Company Across the Border
Helix BioPharma is a Canadian-based biopharmaceutical company that specializes in the field of cancer therapy. With a base of investors in Canada and Europe, the company sought to build its following in the U.S.
READ MORE.
|
|
|
|
 |
|
Introducing a Novel Medical Device to the World
OrbusNeich developed a new cardiac stent unlike any other product on the market. With the stent available in Europe, Asia and Latin America, OrbusNeich approached Russo Partners with the specific goal of generating visibility in the medical community to drive sales.
READ MORE.
|
|
|
|
 |
|
Reading, writing and understanding the code of life
febit is a German company that puts the tools for simplified genomic research in the hands of its customers – and wanted to put those tools in the hands of U.S. researchers. When febit set up operations in the Boston area to sell microarray technologies to life science researchers, the company approached Russo Partners for PR help.
READ MORE.
|
|
|
